comparemela.com
Latest Breaking News On - Department of medicine at roswell park - Page 1 : comparemela.com
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 AIM ImmunoTech Inc. today announced the publication of results from the Phase 1 study at Roswell Park.
New-york
United-states
American
Pawel-kalinski
Shipra-gandhi
Roswell-park
Roswell-park-comprehensive-cancer-center
Immunotech-inc
Department-of-medicine-at-roswell-park
Facebook
Team-science-at-roswell-park
Roswell-park-care-network
vimarsana © 2020. All Rights Reserved.